Mind Medicine (mindmed) INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Daniel Karlin, Chief Medical Officer and a Director of Mind Medicine (MindMed) Inc., sold 10,853 shares of common stock on September 25, 2026 for $36.57 per share.
Robert Barrow, Chief Executive Officer and a Director of Mind Medicine (MindMed) Inc., sold 31,550 shares of common stock on September 25, 2026 for $36.57 per share.
Matthew T. Wiley, Chief Commercial Officer of Mind Medicine (MindMed) Inc., sold 3,097 shares of common stock on September 25, 2026 for $36.57 per share.
Mark Sullivan, Chief Legal Officer of Mind Medicine (MindMed) Inc., sold 14,051 shares of common stock on September 25, 2026 for $36.57 per share.
Brandi Roberts, Chief Financial Officer of Mind Medicine (MindMed) Inc., sold 3,377 shares of common stock on September 25, 2026 for $36.57 per share.
Carol A Vallone, a Director of Mind Medicine (MindMed) Inc., reported multiple transactions in common stock on September 18, 2026.
Andreas Krebs, a Director of Mind Medicine (MindMed) Inc., reported multiple transactions in common stock on September 18, 2026.
Daniel Karlin, Chief Medical Officer of Mind Medicine (MindMed) Inc., received 200,000 shares of common stock on September 14, 2026.
Matthew T. Wiley, Chief Commercial Officer of Mind Medicine (MindMed) Inc., received 125,000 shares of common stock on September 14, 2026.
Mark Sullivan, Chief Legal Officer of Mind Medicine (MindMed) Inc., received 125,000 shares of common stock on September 14, 2026.
Brandi Roberts, Chief Financial Officer of Mind Medicine (MindMed) Inc., received 125,000 shares of common stock on September 14, 2026.
Robert Barrow, Chief Executive Officer and a Director of Mind Medicine (MindMed) Inc., received 750,000 shares of common stock on September 14, 2026.
Robert Barrow, Chief Executive Officer and a Director of Mind Medicine (MindMed) Inc., sold 19,023 shares of common stock on September 2, 2026 for $37.94 per share.
Robert Barrow, Chief Executive Officer and a Director of Mind Medicine (MindMed) Inc., received 375,000 shares of common stock on August 12, 2026.
Daniel Karlin, Chief Medical Officer of Mind Medicine (MindMed) Inc., received 100,000 shares of common stock on August 12, 2026.
Mark Sullivan, Chief Legal Officer of Mind Medicine (MindMed) Inc., received 62,500 shares of common stock on August 12, 2026.
Matthew T. Wiley, Chief Commercial Officer of Mind Medicine (MindMed) Inc., received 62,500 shares of common stock on August 12, 2026.
Brandi Roberts, Chief Financial Officer of Mind Medicine (MindMed) Inc., received 62,500 shares of common stock on August 12, 2026.
Definium Therapeutics Chief Legal Officer Mark Sullivan sold 13,008 common shares to cover tax withholding obligations under a Rule 10b5-1 plan.
Brandi Roberts, Chief Financial Officer of Definium Therapeutics, Inc., sold 3,013 common shares to cover tax withholding obligations as part of a pre-established Rule 10b5-1 trading plan.
Definium Therapeutics CEO Robert Barrow sold 29,208 common shares to cover tax obligations under a Rule 10b5-1 plan.
Definium Therapeutics Chief Medical Officer Daniel Karlin sold 10,035 common shares for $45.03 per share on June 25, 2026, to cover tax withholding obligations under a Rule 10b5-1 plan.
Definium Therapeutics Chief Commercial Officer Matthew T. Wiley sold 2,867 common shares to cover tax withholding obligations under a Rule 10b5-1 plan.
Definium Therapeutics Director Roger Crystal reports acquisition of restricted stock units and stock options, alongside beneficial ownership of common shares.
David W. Gryska, a Director at Definium Therapeutics, Inc., has reported the acquisition of restricted stock units and the exercise of stock options.
Carol Vallone, a Director at Definium Therapeutics, Inc., has acquired 4,666 common shares and a stock option for 19,188 shares, as detailed in a Form 4 filing.
Andreas Krebs, a Director at Definium Therapeutics, Inc., reported the acquisition of 4,666 restricted stock units and the grant of 19,188 stock options on June 11, 2026.
Roger Adsett, a Director at Definium Therapeutics, Inc., reported the acquisition of 3,555 common shares and a stock option for 14,620 shares.
Suzanne Bruhn, a Director at Definium Therapeutics, Inc., reported transactions involving stock options and restricted stock units.
Definium Therapeutics' Chief Medical Officer, Daniel Karlin, sold 8,018 common shares at a weighted average price of $18.47 to cover tax obligations from vested restricted stock units.